Pharmacogenomics of Cisplatin‐Induced Ototoxicity: Successes, Shortcomings, and Future Avenues of Research

Cisplatin is a highly effective chemotherapeutic. Unfortunately, its use is limited by cisplatin‐induced ototoxicity (CIO). Substantial research has been performed to uncover the genetic variants associated with CIO; however, there has been a lack of consistency in the results that have been reporte...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2019-08, Vol.106 (2), p.350-359
Main Authors: Drögemöller, Britt I., Wright, Galen E.B., Lo, Cody, Le, Tan, Brooks, Beth, Bhavsar, Amit P., Rassekh, Shahrad R., Ross, Colin J.D., Carleton, Bruce C.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Cisplatin - pharmacology
Humans
Ototoxicity - etiology
Ototoxicity - genetics
Pharmacogenetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cisplatin is a highly effective chemotherapeutic. Unfortunately, its use is limited by cisplatin‐induced ototoxicity (CIO). Substantial research has been performed to uncover the genetic variants associated with CIO; however, there has been a lack of consistency in the results that have been reported. This paper aims to provide an overview of the current state of CIO genomics research, delving into the shortcomings of past research, and providing recommendations for future avenues of study.
ISSN:0009-9236
1532-6535
DOI:10.1002/cpt.1483